ANTI-C-MYC

Gefahreninformationscode (GHS)

• Bildanzeige (GHS)

  

• Alarmwort

  Warnung

• Gefahrenhinweise

  H317：Kann allergische Hautreaktionen verursachen.

• Sicherheit

  P261：Einatmen von Staub vermeiden.

  P272：Kontaminierte Arbeitskleidung nicht außerhalb des Arbeitsplatzes tragen.

  P280：Schutzhandschuhe/Schutzkleidung/Augenschutz tragen.

  P302+P352：BEI BERÜHRUNG MIT DER HAUT: Mit viel Wasser/... (Hersteller kann, falls zweckmäßig, ein Reinigungsmittel angeben oder, wenn Wasser eindeutig ungeeignet ist, ein alternatives Mittel empfehlen) waschen.

  P333+P313：Bei Hautreizung oder -ausschlag: Ärztlichen Rat einholen/ärztliche Hilfe hinzuziehen.

ANTI-C-MYC Chemische Eigenschaften,Einsatz,Produktion Methoden

• Verwenden

  Monoclonal Anti-MYC-FITC , (C-terminal) antibody produced in mouse has been used in immunofluorescence and flow cytometry.

• Verwenden

  Use Anti-c-myc for the detection of native human c-myc protein and recombinant epitope-tagged proteins that contain the c-myc epitope using:
  
  • Dot blots
  • Immunocytochemistry
  • Immunoprecipitation
  • Western blots
  • Immunohistochemistry.

• Allgemeine Beschreibung

  The Anti-c-Myc peroxidase conjugate rabbit antibody reacts with c-Myc tagged fusion proteins. It recognizes the c-Myc tag sequence expressed at either the amino- or the carboxyl-terminus.

• Biochem/physiol Actions

  The cellular myelocytomatosis (c-myc) oncogene has a crucial role in cellular proliferation, differentiation, apoptosis and acts as transcriptional regulator of gene expression. c-myc expression is essential and sufficient to assist most of the cells to enter DNA synthetic (S) phase of the cell cycle. The encoded protein plays a crucial role in vasculogenesis and angiogenesis during cancer development and progression. c-myc interacts with its binding partner Max and activates the transcription of growth promoting genes such as cyclin D2 and ornithine decarboxylase. It also represses the transcription of multiple genes, especially p21 and p27, by binding to the transcription initiator element (Inr) in a complex with Max and either Sp1 (specificity protein 1) or Miz1 (Myc-interacting zinc finger protein 1). Overexpression of MYC in DLBCL (diffuse large B-cell lymphoma) results in poor outcome and invasive treatment when medicated with rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP).

ANTI-C-MYC Anbieter Lieferant Produzent Hersteller Vertrieb Händler.

Global(47)Suppliers